Antimicrobial stewardship program in COVID-19 era: Ruin of the reign?

Authors

  • Arash Eatemadi Infectious Disease Specialist, Hospital Stewardship Committee, Suhar Hospital, Suhar, Sultanate of Oman
  • Sirous Golchinheydari National University of Science and Technology, Suhar, Sultanate of Oman
  • Mohammed Al Reesi Pediatric Infectious Diseases Consultant, Head of Paediatrics Department, Head of Hospital Stewardship Committee, Suhar Hospital, Suhar, Sultanate of Oman
  • Majid Al Maqbali Family Medicine Consultant, Suhar Hospital, Suhar, Sultanate of Oman
  • Talib Al Maqbali Maqbali ENT Consultant, Head of Surgical Divisions, Suhar Hospital, Suhar, Sultanate of Oman
  • Aiman Al Wahaibi Internal Medicine Specialist, Department of General Medicine, Suahr Hospital, Sultanate of Oman

DOI:

https://doi.org/10.32553/jbpr.v9i6.822

Keywords:

COVID-19, Antibiotic stewardship program (ASP), Superbugs

Abstract

COVID-19 is the most important matter in the medical field worldwide in 2020. Although COVID-19 is a viral disease, the threshold to antibiotic prescription for COVID-19 patients is low, partly because of WHO recommendations and previous experiences from influenza, despite the lack of strong evidence of co-infection or superimposed bacterial infection in COVID-19 patients. Antibiotic stewardship program (ASP) could play an important role in this period, otherwise, we will face a crisis of superbugs in the early future.

Keywords:  COVID-19, Antibiotic stewardship program (ASP), Superbugs

Downloads

Published

2021-01-08

How to Cite

Eatemadi, A. ., Golchinheydari, S. ., Reesi, M. A. ., Maqbali, M. A. . ., Maqbali, T. A. M. ., & Wahaibi, A. A. . (2021). Antimicrobial stewardship program in COVID-19 era: Ruin of the reign?. Journal of Biomedical and Pharmaceutical Research, 9(6), 31–33. https://doi.org/10.32553/jbpr.v9i6.822

Issue

Vol. 9 No. 6 (2020)

Section

Opinions and Perspective

License

Creative Commons LicenseJournal of Biomedical and Pharmaceutical Research by Articles is licensed under a Creative Commons Attribution 4.0 International License.